Myotonic Muscular Dystrophy

2

Review clinical trials related to Myotonic Muscular Dystrophy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

Myotonic Dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder that causes progressive disability and shortened life expectancy. It is characterized by progressive weakness and myotonia, which preferentially affects the craniofacial, hand, and distal leg muscles. Many patients also experience difficulties with cognition, cardiac arrhythmias, respiratory failure, or cataracts. Currently there is no treatment to slow progression or reverse the symptoms.

Participants needed: 1,000
Trial details
Age: 18-70Biological sex: AllType: ObservationalSponsor: Virginia Commonwealth UniversityUpdated: Jul 13, 2026Locations: 1Duration: 4 Years
Eligibility criteria

Age 18 to 70 years (inclusive) [+2]

Symptomatic renal or liver disease, uncontrolled diabetes or thyroid disorder, o... [+4]

Status: Recruiting

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue. The purpose of this registry is to connect people with DM or FSHD with researchers studying these diseases. The registry will offer individuals with DM and FSHD an opportunity to participate in research that focuses of their diseases. The registry will also help scientists to accomplish research on DM and FSHD and to distribute their findings to patients and care providers.

Participants needed: 3,000
Trial details
Biological sex: AllType: ObservationalSponsor: University of RochesterUpdated: Oct 15, 2025Locations: 1
Eligibility criteria

Diagnosed with DM, FSHD, or related diseases or are an unaffected family member...